Walnut Component rJug r 3
This assay is used to detect allergen specific-IgE using the ImmunoCAP® FEIA method. In vitro allergy testing is the primary testing mode for allergy diagnosis.
The ImmunoCAP® FEIA method uses as the solid phase a flexible, hydrophobic cellulosic polymer to which allergen has been covalently linked. The advantage of this system is that it has a very high antigen binding capacity when compared to other systems and it has minimal non-specific binding with high total IgE. Viracor Eurofins provides an optional low range calibrator at 0.1 kU/L and a 0/1 class. This test has been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
1-2 business days from receipt of specimen
|Specimen Type||Order Code||CPT Code||NY Approved||Volume||Assay Range||Special Instructions|
|serum||30287||86003||Yes||0.5 mL||See Scoring Guide||
ImmunoCAP® Quantitative Scoring Guide: Class IgE (kU/L) Comment 0 99.99 Very High Positive Note that Viracor Eurofins includes an extra calibrator at 0.10 kU/L and uses it todefine an optional equivocal class.
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Viracor Eurofins test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Viracor Eurofins, 1001 NW Technology Dr, Lee's Summit, MO 64086.
Lipemic samples may lead to rejection.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above. The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
Borja J et al. Anaphylaxis from Brazil nut. Allergy 54, 1999 / 1004-1013. Clark A et al. Cashew nut causes more severe reactions than peanut: case-matched comparison in 141 children. Allergy 2007; 62(8): 913-6. Davoren M et al. Cashew nut allergy is associated with a high risk of anaphylaxis. Arch Dis Child 2005; 90(10): 1084-5. Egger m et al. The Role of Lipid Transfer Proteins in Allergic Diseases. Curr Allergy Asthma Rep 2010; 10:326-335. Masthoff L et al. A systematic review of the effect of thermal processing on the allergenicity of tree nuts. Allergy. 2013; 68: 983-993. Pastorello E et al. Lipid transfer protein and vicilin are important walnut allergens in patients not allergic to pollen. J Allergy Clin Immunol 2004; 114940: 908-14. Robotham J et al. Ana o 3, an important cashew nut (Anacardium occidentale L.) allergen of the 2S albumin family. J Allergy Clin Immunol. 2005; 115(6): 1284-90. Rosenfeld L et al. Walnut Allergy in Peanut-Allergic Patients: Significance of Sequential Epitopes of Walnut Homologous to Linear Epitopes of Ara h 1, 2 and 3 in Relation to Clinical Reactivity. Int Arch Allergy Immunol. 2012; 157: 238-245. Roux K et al. Tree nut allergens. Int Arch Allergy Immunology 2003; 131: 234-244. Wang F et al. Ana o 2, a major cashew (Anacardium occidentale L.) nut allergen of the legumin family. Int Arch Allergy Immunol. 2003 Sep: 132(1): 27-39. www.phadia.com